Neurocrine Biosciences, Inc.
NBIX
$128.91
$0.680.53%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 20.07% | -8.78% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 20.07% | -8.78% | |||
| Cost of Revenue | -6.17% | 39.76% | |||
| Gross Profit | 43.87% | -30.64% | |||
| SG&A Expenses | 3.54% | -8.38% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -1.28% | 10.51% | |||
| Operating Income | 514.35% | -81.91% | |||
| Income Before Tax | 985.03% | -90.96% | |||
| Income Tax Expenses | 664.71% | -88.57% | |||
| Earnings from Continuing Operations | 1,260.76% | -92.34% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 1,260.76% | -92.34% | |||
| EBIT | 514.35% | -81.91% | |||
| EBITDA | 388.50% | -77.34% | |||
| EPS Basic | 1,271.09% | -92.32% | |||
| Normalized Basic EPS | 268.66% | -70.34% | |||
| EPS Diluted | 1,238.38% | -92.09% | |||
| Normalized Diluted EPS | 271.57% | -70.31% | |||
| Average Basic Shares Outstanding | -0.70% | -0.30% | |||
| Average Diluted Shares Outstanding | -1.46% | -0.39% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||